FNY Investment Advisers LLC lessened its stake in Quotient Ltd (NASDAQ:QTNT) by 46.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,000 shares of the company’s stock after selling 40,400 shares during the quarter. FNY Investment Advisers LLC’s holdings in Quotient were worth $346,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Trexquant Investment LP purchased a new position in shares of Quotient in the 2nd quarter valued at about $102,000. West Chester Capital Advisors Inc. purchased a new position in shares of Quotient in the 2nd quarter valued at about $120,000. Bank of America Corp DE increased its holdings in shares of Quotient by 539.0% in the 2nd quarter. Bank of America Corp DE now owns 16,768 shares of the company’s stock valued at $135,000 after purchasing an additional 14,144 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Quotient by 341.8% in the 1st quarter. The Manufacturers Life Insurance Company now owns 21,820 shares of the company’s stock valued at $103,000 after purchasing an additional 16,881 shares in the last quarter. Finally, Cim Investment Mangement Inc. purchased a new position in shares of Quotient in the 2nd quarter valued at about $407,000. Institutional investors and hedge funds own 49.25% of the company’s stock.
A number of equities analysts have recently issued reports on QTNT shares. Zacks Investment Research upgraded shares of Quotient from a “sell” rating to a “hold” rating in a report on Wednesday, October 10th. ValuEngine downgraded shares of Quotient from a “buy” rating to a “hold” rating in a report on Wednesday, September 12th. Finally, BidaskClub downgraded shares of Quotient from a “hold” rating to a “sell” rating in a report on Friday, September 21st. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $11.50.
Quotient (NASDAQ:QTNT) last issued its quarterly earnings data on Tuesday, August 7th. The company reported ($0.55) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.18). The company had revenue of $7.88 million for the quarter, compared to analysts’ expectations of $6.90 million. Equities analysts anticipate that Quotient Ltd will post -1.64 earnings per share for the current year.
Quotient Company Profile
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.
Want to see what other hedge funds are holding QTNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quotient Ltd (NASDAQ:QTNT).
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.